Autobahn raises $100M on investor interest in neuropsych drugs
Bio Pharma Dive
JULY 24, 2024
Autobahn’s lead candidate is designed to stimulate thyroid hormone receptors as a way to complement existing antidepressants.
Wed.Jul 24, 2024
290 
Standing ovation for Gilead as it boasts perfect efficacy in HIV PReP trial
Pharmaceutical Technology
JULY 24, 2024
The crowd and panel gave Gilead a standing ovation after the full data from the Phase III PURPOSE trial was announced at AIDS 2024.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mice That Eat Less Live Longer – And We May Finally Know Why
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 24, 2024
We’ve known for over a century that mice and rats live longer when they are fed less, but a new study reveals the secret might be an imbalance between energy consumed and burned, rather than a lack of energy or protein.
Pfizer says hemophilia gene therapy meets late-stage study goal
Bio Pharma Dive
JULY 24, 2024
While the study results were positive, questions remain about the longer-term potential of hemophilia treatments like Pfizer’s.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
India’s lower-income groups severely impacted with financial challenges to treat cancer
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 24, 2024
India’s lower-income groups face significant financial challenges when it comes to cancer treatment. High medical costs, lack of insurance coverage, and limited access to quality healthcare services exacerbate the situation. Many families are seen to opt between basic necessities and treatment, leading to increased mortality rates and a higher burden of disease.
Triastek and BioNTech to develop 3D-printed RNA therapeutics
Pharmaceutical Technology
JULY 24, 2024
BioNTech and Triastek have entered a research partnership focusing on the development of 3D-printed oral RNA therapeutics.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Study suggests targeting amyloid beta production could be promising in AD
Pharma Times
JULY 24, 2024
The neurodegenerative disease is currently the most common cause of dementia
Biogen, Sage tremor drug fails key trial
Bio Pharma Dive
JULY 24, 2024
Known as SAGE-324, the drug was one of the key assets Biogen gained rights to through a billion-dollar research deal inked back in 2020.
July 24, 2024: In This Week’s PCT Grand Rounds, Fonarow to Discuss Interventions for Optimizing Guideline-Directed Medical Therapy
Rethinking Clinical Trials
JULY 24, 2024
In this Friday’s PCT Grand Rounds, Gregg Fonarow of the University of California, Los Angeles, will present “Interventions for Optimization of Guideline-Directed Medical Therapy.” The Grand Rounds session will be held on Friday, July 26, 2024, at 1:00 pm eastern. Fonarow is the Eliot Corday Professor of Cardiovascular Medicine and Science at UCLA, director of the Ahmanson-UCLA Cardiomyopathy Center, and codirector of the UCLA Preventative Cardiology Program.
FDA medical device chief Shuren to step down after 15 years
Bio Pharma Dive
JULY 24, 2024
Michelle Tarver, deputy director for transformation, will serve as acting director of the FDA’s medical devices office.
BioAtla receives FDA fast track designation for ozuriftamab vedotin
Pharmaceutical Technology
JULY 24, 2024
The Phase II antibody drug conjugate received FDA fast track designation against treatment-resistant head and neck carcinoma.
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
Bio Pharma Dive
JULY 24, 2024
The Swiss pharma is paying Dren Bio $150 million to partner on “targeted myeloid engagers.” Elsewhere, Geron is losing its commercial chief and Biovectra will sell to Agilent for $925 million.
The potential of 3D printing in drug development and delivery
Pharmaceutical Technology
JULY 24, 2024
3D printing is replacing traditional prototype development approaches across various industries, and use in healthcare is increasing fast.
ASCO 2024 - Matteo Levisetti
pharmaphorum
JULY 24, 2024
Stay updated on Matteo Levisetti, the chief medical officer at CUE Biopharma, post ASCO 2024. Learn about his latest research and contributions in the field of biopharma.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
AstraZeneca grows oncology portfolio with Pinetree’s EGFR degrader
Pharmaceutical Technology
JULY 24, 2024
AstraZeneca will pay $45m upfront and up to $500m in milestone-based payments for licencing Pinetree’s preclinical EGFR degrader.
FDA blasts Indian CDMO Brassica for 'routine' data falsification, poor hygiene and more
Fierce Pharma
JULY 24, 2024
From flubbing data to performing aseptic processing with torn and stained gowns, Brassica Pharma’s recent warning letter from the FDA reads like a textbook example of what not to do when the U.S. | From flubbing data to performing aseptic processing with torn and stained gowns, Brassica Pharma’s recent warning letter from the FDA reads like a textbook example of what not to do when the U.S. regulator comes knocking at your facility.
New study suggests CAR-T therapy monitoring time could be slashed
Pharmaceutical Technology
JULY 24, 2024
The study found that the risk of certain side effects peak by two weeks for lymphoma patients receiving three CAR-T therapies.
DIA 2024: Charting new horizons in patient-centered R&D
pharmaphorum
JULY 24, 2024
Explore the latest developments in the life sciences industry with a focus on patient-centred research and development (R&D) at DIA 2024. Chart new horizons and stay updated on key trends shaping the future of healthcare.
Telix’s prostate cancer imaging kit set for FDA review
Pharmaceutical Technology
JULY 24, 2024
Telix’s ‘cold kit’ will “improve equity of access” to PSMA-PET imaging, the company’s CEO says.
PBMs under the cosh at House hearing on drug pricing
pharmaphorum
JULY 24, 2024
The top three pharmacy benefit managers in the US felt the heat at a hearing of the House Oversight Committee, as lawmakers grilled executives over their business practices and accused them of monopolising the supply chain.
BeiGene opens biologics facility in New Jersey, US
Pharmaceutical Technology
JULY 24, 2024
BeiGene has announced the opening of its new US biologics manufacturing and clinical R&D facility at Hopewell, New Jersey.
BeiGene CEO eyes biologics deals for new US innovation center in New Jersey
Fierce Pharma
JULY 24, 2024
HOPEWELL, NEW JERSEY—A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics. | A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
MHRA approves Novo Nordisk’s semaglutide to cut cardiovascular risk
Pharmaceutical Technology
JULY 24, 2024
The UK MHRA has approved a new indication of Novo Nordisk’s semaglutide to lower the risk of serious heart problems in overweight adults.
Asarina folds as it ends search for Tourette's drug partner
pharmaphorum
JULY 24, 2024
Asarina Pharma has abandoned its partner search for Tourette's drug sepranolone and will go into liquidation.
Merck and GTRI to develop gene therapy for Parkinson’s disease
Pharmaceutical Technology
JULY 24, 2024
Merck has entered a non-binding MoU with the Gene Therapy Research Institution (GTRI) to produce a gene therapy for Parkinson's disease.
ICL study finds single bowel screening test can reduce chances of developing cancer
Pharma Times
JULY 24, 2024
Affecting over 250,000 people, bowel cancer is the fourth most common cancer in the UK
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
The new frontiers of supply chain disruption – and how pharma firms are responding
Pharmaceutical Technology
JULY 24, 2024
The pharmaceutical industry is facing supply chain challenges, resulting in drug shortages and prompting reorganisation by the pharma sector.
Pharma Pulse 7/24/24: Addressing OUD Treatment Gaps, Body Dysmorphic Disorder Most Common in Adolescent Girls & more
Pharmaceutical Commerce
JULY 24, 2024
The latest news for pharma industry insiders.
Pipeline power: Sionna’s AbbVie deal could redefine CF therapeutics
Pharmaceutical Technology
JULY 24, 2024
Sionna Therapeutic has strengthened its position in the cystic fibrosis (CF) therapeutic landscape through a licensing agreement with AbbVie.
The Regulatory Maze: How Generic Drugs Navigate FDA Approval
Drug Patent Watch
JULY 24, 2024
In the high-stakes world of pharmaceuticals, generic drugs have become the unsung heroes of healthcare accessibility.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content